UK markets closed

Design Therapeutics, Inc. (DSGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.7300+0.0800 (+2.19%)
As of 12:54PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 206.20M
Enterprise value -72.54M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.74
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.93

Trading information

Stock price history

Beta (5Y monthly) 1.83
52-week change 3-43.59%
S&P500 52-week change 322.64%
52-week high 38.4700
52-week low 31.9400
50-day moving average 33.2126
200-day moving average 33.1820

Share statistics

Avg vol (3-month) 3264.09k
Avg vol (10-day) 3299.95k
Shares outstanding 556.49M
Implied shares outstanding 656.65M
Float 824.14M
% held by insiders 136.67%
% held by institutions 156.76%
Shares short (15 Apr 2024) 42.39M
Short ratio (15 Apr 2024) 46.07
Short % of float (15 Apr 2024) 47.00%
Short % of shares outstanding (15 Apr 2024) 44.23%
Shares short (prior month 15 Mar 2024) 42.14M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-15.49%
Return on equity (ttm)-22.10%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -77.65M
Net income avi to common (ttm)-66.86M
Diluted EPS (ttm)-1.1900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)281.8M
Total cash per share (mrq)4.99
Total debt (mrq)3.05M
Total debt/equity (mrq)1.10%
Current ratio (mrq)29.58
Book value per share (mrq)4.92

Cash flow statement

Operating cash flow (ttm)-58.56M
Levered free cash flow (ttm)-34.78M